Literature DB >> 21890592

Clinical and pathogenic aspects of candidate genes for lithium prophylactic efficacy.

Janusz K Rybakowski1, Piotr Czerski, Monika Dmitrzak-Weglarz, Sebastian Kliwicki, Anna Leszczynska-Rodziewicz, Agnieszka Permoda-Osip, Maria Skibinska, Aleksandra Suwalska, Aleksandra Szczepankiewicz, Joanna Hauser.   

Abstract

A number of candidate genes for lithium prophylactic efficacy have been proposed, some of them being also associated with a predisposition to bipolar illness. The aim of the present study was to investigate a possible association between polymorphisms of 14 common genes with the quality of prophylactic lithium response in patients with bipolar mood disorder, in relation to the putative role of these genes in the pathogenesis of this disorder. Some association with lithium prophylactic efficacy was found for the polymorphisms of 5HTT, DRD1, COMT, BDNF and FYN genes, but not for 5HT2A, 5HT2C, DRD2, DRD3, DRD4, GSK-3, NTRK2, GRIN2B and MMP-9. Possible aspects of these genes with regard to the mechanism of lithium activity and pathogenesis of bipolar mood disorder are discussed.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21890592     DOI: 10.1177/0269881111415736

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  8 in total

Review 1.  The Role of Pharmacogenomics in Bipolar Disorder: Moving Towards Precision Medicine.

Authors:  Claudia Pisanu; Urs Heilbronner; Alessio Squassina
Journal:  Mol Diagn Ther       Date:  2018-08       Impact factor: 4.074

2.  Meta-analysis demonstrates lack of association of the GSK3B -50C/T polymorphism with risk of bipolar disorder.

Authors:  Guodi Chen; Jun Tang; Guangwei Yu; Yiping Chen; Liancong Wang; Yao Zhang
Journal:  Mol Biol Rep       Date:  2014-06-15       Impact factor: 2.316

3.  Neurotrophic tyrosine kinase receptor type 2 (NTRK2) gene associated with treatment response to mood stabilizers in patients with bipolar I disorder.

Authors:  Zuowei Wang; Jinbo Fan; Keming Gao; Zezhi Li; Zhenghui Yi; Lingxiao Wang; Jia Huang; Chengmei Yuan; Wu Hong; Shunying Yu; Yiru Fang
Journal:  J Mol Neurosci       Date:  2013-01-15       Impact factor: 3.444

Review 4.  The Genetics of Response to and Side Effects of Lithium Treatment in Bipolar Disorder: Future Research Perspectives.

Authors:  Fanny Senner; Mojtaba Oraki Kohshour; Safa Abdalla; Sergi Papiol; Thomas G Schulze
Journal:  Front Pharmacol       Date:  2021-03-25       Impact factor: 5.810

Review 5.  Genetic and Epigenetic Markers of Lithium Response.

Authors:  Claudia Pisanu; Anna Meloni; Giovanni Severino; Alessio Squassina
Journal:  Int J Mol Sci       Date:  2022-01-29       Impact factor: 5.923

6.  Investigation of inflammation related gene polymorphism of the mannose-binding lectin 2 in schizophrenia and bipolar disorder.

Authors:  Hasan M Aytac; Menekse S Yazar; Ayse Erol; Sacide Pehlivan
Journal:  Neurosciences (Riyadh)       Date:  2021-10       Impact factor: 0.735

7.  Genetic variation in the human brain dopamine system influences motor learning and its modulation by L-Dopa.

Authors:  Kristin M Pearson-Fuhrhop; Brian Minton; Daniel Acevedo; Babak Shahbaba; Steven C Cramer
Journal:  PLoS One       Date:  2013-04-17       Impact factor: 3.240

Review 8.  Genetic influences on response to mood stabilizers in bipolar disorder: current status of knowledge.

Authors:  Janusz K Rybakowski
Journal:  CNS Drugs       Date:  2013-03       Impact factor: 5.749

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.